Brokerages Expect Radius Health, Inc. (NASDAQ:RDUS) to Post -$0.39 EPS

Wall Street brokerages expect Radius Health, Inc. (NASDAQ:RDUS) to post earnings per share (EPS) of ($0.39) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Radius Health’s earnings. The lowest EPS estimate is ($0.69) and the highest is $0.11. Radius Health reported earnings per share of ($0.54) in the same quarter last year, which would suggest a positive year-over-year growth rate of 27.8%. The firm is expected to issue its next earnings report before the market opens on Thursday, February 25th.

On average, analysts expect that Radius Health will report full-year earnings of ($2.27) per share for the current financial year, with EPS estimates ranging from ($2.58) to ($1.77). For the next year, analysts forecast that the company will post earnings of ($1.05) per share, with EPS estimates ranging from ($1.45) to ($0.24). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that cover Radius Health.

Several equities research analysts have recently issued reports on the stock. HC Wainwright reiterated a “hold” rating on shares of Radius Health in a research report on Thursday, January 7th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their price target on Radius Health from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, January 7th. SVB Leerink upped their price objective on Radius Health from $17.00 to $20.00 and gave the stock a “market perform” rating in a report on Thursday, January 7th. Smith Barney Citigroup lifted their target price on Radius Health from $25.00 to $30.00 in a research report on Thursday, January 7th. Finally, Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Monday, January 11th. Six research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $22.60.

NASDAQ RDUS traded up $0.02 during trading hours on Tuesday, reaching $18.62. The company’s stock had a trading volume of 21,677 shares, compared to its average volume of 442,362. Radius Health has a 1 year low of $10.15 and a 1 year high of $23.84. The company has a market capitalization of $866.71 million, a price-to-earnings ratio of -7.62 and a beta of 1.18. The firm’s 50-day moving average price is $20.90 and its 200-day moving average price is $15.67.

Several hedge funds have recently modified their holdings of RDUS. Marshall Wace LLP purchased a new stake in Radius Health during the 1st quarter valued at about $371,000. First Trust Advisors LP purchased a new position in shares of Radius Health during the first quarter worth $1,320,000. Bank of America Corp DE raised its stake in shares of Radius Health by 69.1% during the 2nd quarter. Bank of America Corp DE now owns 31,889 shares of the biopharmaceutical company’s stock valued at $434,000 after buying an additional 13,026 shares during the last quarter. Pacer Advisors Inc. acquired a new stake in Radius Health during the third quarter worth about $36,000. Finally, DekaBank Deutsche Girozentrale acquired a new position in Radius Health in the third quarter valued at approximately $166,000.

About Radius Health

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS, an anabolic agent for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in phase 3 clinical study for the treatment of osteoporosis in men; abaloparatide transdermal patch, a short-wear-time patch, that is in phase 3 clinical study to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in phase 3 clinical study for the treatment of hormone receptor-positive breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator, which is in phase 1A clinical study to treat metastatic breast cancer.

Further Reading: Correction

Get a free copy of the Zacks research report on Radius Health (RDUS)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with's FREE daily email newsletter.